Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
D 2.31 -4.94% -0.12
MESO closed down 4.94 percent on Monday, March 18, 2024, on 34 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Calm After Storm Range Contraction -4.94%
Outside Day Range Expansion -4.94%
Wide Bands Range Expansion -4.94%
Gapped Down Weakness -4.94%
1,2,3 Pullback Bullish Bullish Swing Setup -5.33%
180 Bullish Setup Bullish Swing Setup -5.33%

   Recent Intraday Alerts

Alert Time
Gap Down Partially Closed about 21 hours ago
Gapped Down (Partial) about 22 hours ago
Down 5% about 22 hours ago
Down 3% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mesoblast Limited Description

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Stem Cell Bone Cardiovascular Disease Heart Failure Therapeutic Products Hematology Rheumatoid Arthritis Vascular Disease Spine Pharmaceutical Industries Transplantation Bone Marrow Diabetic Nephropathy Congestive Heart Failure Host Disease Skeletal Disorders Spinal Fusion Adult Stem Cell Back Pain Cell Product Graft Versus Host Disease Ischemia Degenerative Disc Disease Inflammatory Conditions Teva Pharmaceutical Industries Mesoblast Cardiac Diseases Musculoskeletal Disorders Regenerative Biomedicine

Is MESO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.24
52 Week Low 1.61
Average Volume 458,898
200-Day Moving Average 3.65
50-Day Moving Average 2.00
20-Day Moving Average 2.20
10-Day Moving Average 2.35
Average True Range 0.18
RSI (14) 56.71
ADX 36.14
+DI 36.20
-DI 15.70
Chandelier Exit (Long, 3 ATRs) 2.64
Chandelier Exit (Short, 3 ATRs) 2.46
Upper Bollinger Bands 2.62
Lower Bollinger Band 1.77
Percent B (%b) 0.64
BandWidth 38.31
MACD Line 0.13
MACD Signal Line 0.11
MACD Histogram 0.0218
Fundamentals Value
Market Cap 198.23 Million
Num Shares 85.8 Million
EPS -0.86
Price-to-Earnings (P/E) Ratio -2.69
Price-to-Sales 21.62
Price-to-Book 0.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.50
Resistance 3 (R3) 2.49 2.41 2.47
Resistance 2 (R2) 2.41 2.37 2.42 2.46
Resistance 1 (R1) 2.36 2.34 2.33 2.37 2.45
Pivot Point 2.29 2.29 2.27 2.29 2.29
Support 1 (S1) 2.24 2.24 2.20 2.25 2.17
Support 2 (S2) 2.16 2.21 2.17 2.16
Support 3 (S3) 2.11 2.16 2.15
Support 4 (S4) 2.12